Inebilizumab - CAS 1299440-37-1

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

Immunology/Inflammation related, ADC Antibody

Immunology/Inflammation, Antibody-drug Conjugate/ADC Related

1299402

0.993

-20°C

Ice Packs

Inhibitory Antibodies